

BRIEF COMMUNICATION

Progressive decline of glucocerebrosidase in aging and Parkinson's disease

Emily M. Rocha^{1,a}, Gaynor A. Smith^{1,a}, Eric Park², Hongmei Cao², Eilish Brown², Penelope Hallett¹ & Ole Isacson¹¹Neuroregeneration Laboratories, Harvard Medical School, McLean Hospital, Belmont, Massachusetts, 02478²Shire, 300 Shire Way, Lexington, Massachusetts, 02421**Correspondence**

Ole Isacson, Neuroregeneration Research Institute, Harvard Medical School/McLean Hospital, McLean Hospital/Harvard Medical School, 115 Mill Street, Belmont, MA 02478. Tel: (617) 855-3243; Fax: 617-855-3284; E-mail: isacson@hms.harvard.edu

Funding Information

This work was supported by the Harvard Stem Cell Institute Translational Neuroscience Fund, the Harold and Ronna Cooper family, the Consolidated Anti-Aging Foundation, the Poul Hansen family, and the Canadian Institute of Health Research.

Received: 19 December 2014; Accepted: 29 December 2014

Annals of Clinical and Translational Neurology 2015; 2(4): 433–438

doi: 10.1002/acn3.177

^aThese authors contributed equally to this work.

Introduction

Parkinson's disease (PD) is relatively rare before age 40, after age 50 the prevalence rises almost exponentially.¹ By the eighth decade, the estimated prevalence in European and North American populations is between 1000 and 3000 cases per 100,000 population.¹ This age-related risk may be related to the convergence of genetic impairments and age-related decline in cellular function, which include deficits in degradation pathways and elevated mitochondrial damage. As neurons age, they show signs of increased oxidative stress, disturbances in mitochondrial function, and accumulation of misfolded proteins, which are exacerbated in PD. If the role of lysosomal function could be better defined during the aging process, this

Abstract

The principal risk factor for developing most adult onset neurodegenerative diseases is aging, with incidence rising significantly after age 50. Despite research efforts, the causes of Parkinson's disease (PD) remain unknown. As neurons age, they show signs of diminished lysosomal and mitochondrial function, including increased oxidative stress and accumulation of misfolded proteins, and these changes become exacerbated PD. We show that activity of the lysosomal hydrolase glucocerebrosidase gradually diminishes with age in the substantia nigra and putamen of healthy controls. This reduction is comparable to glucocerebrosidase activity in *GBA1*-mutation carrier PD patients. These data, demonstrate for the first time that an age-dependent reduction in glucocerebrosidase activity may lower the threshold for developing PD.

may lead to more effective therapeutic options to treat PD.

Neuronal aging is unique because neurons are postmitotic cells, and therefore they rely heavily on protein clearance mechanisms to maintain homeostasis. The two major proteolytic systems responsible for intracellular protein turnover are the autophagy-lysosomal system and the ubiquitin-proteasome system. Aging lysosomal systems undergo dramatic changes including, increased volume and decreased stability and accumulation of indigestible materials.² This is significant given that lysosomes are responsible for the clearance of proteins, such as α -synuclein as well as the removal of damaged organelles, such as mitochondria.^{3,4} The gene *GBA1* encodes for the lysosomal hydrolase glucocerebrosidase (GCCase), and

Table 1. Parkinson's disease and control case information.

Patient ID	Diagnosis	Age	Sex	PMI
AN15395	Control	74	Male	18.58
AN18990	Control	71	Male	17.41
AN15515	Control	73	Male	20.88
AN17230	Control	68	Male	26.52
AN06318	Control	66	Male	17.83
AN13687	Control	73	Female	24.88
AN06749	Control	75	Male	23.97
AN04648	Control	73	Male	32.68
AN08704	Control	70	Male	23.5
AN06429	Control	77	Male	23.25
AN05049	Control	78	Male	35.17
AN01717	Control	79	Male	20.6
AN01234	Control	85	Male	20.83
AN01219	Control	83	Male	8.86
AN16467	Control	79	Female	26.67
AN06669	Control	81	Male	23.33
AN06400	Control	91	Male	23.48
AN05090	Control	87	Male	21.12
8201	Control	74	Male	24.62
8155	Control	58	Male	20.47
8136	Control	76	Male	12.25
8134	Control	77	Female	20.61
8113	Control	51	Male	28.82
7559	Control	78	Male	19
7542	Control	76	Male	24
7519	Control	55	Male	24
7516	Control	63	Male	20
7508	Control	62	Male	26
7458	Control	77	Male	29
AN01987	Parkinson's disease	74	Male	21.08
AN08649	Parkinson's disease	71	Male	12.8
AN01756	Parkinson's disease	69	Male	7.1
AN01131	Parkinson's disease	68	Male	16.82
AN06530	Parkinson's disease	64	Male	17.75
AN02428	Parkinson's disease	75	Male	19.42
AN18072	Parkinson's disease	73	Male	4.5
AN12683	Parkinson's disease	77	Male	20.67
AN02532	Parkinson's disease	79	Male	21.12
AN12710	Parkinson's disease	87	Male	5.58
AN01459	Parkinson's disease	87	Male	12.3
AN15147	Parkinson's disease	82	Female	18.08
AN02821	Parkinson's disease	81	Male	23
AN11926	Parkinson's disease	84	Male	13.82
AN13686	Parkinson's disease	88	Male	24.25
8118	Parkinson's disease	83	Male	15.03
8095	Parkinson's disease	70	Male	22.92
8091	Parkinson's disease	71	Male	23.42
8067	Parkinson's disease	75	Male	26.08
AN05419	Parkinson's disease	76	Male	13
AN05440	Parkinson's disease	77	Male	18
AN06461	Parkinson's disease	87	Male	28
AN18571	Parkinson's disease	70	Male	20
AN10634	Parkinson's disease	86	Male	20
AN10333	Parkinson's disease	74	Male	30

PMI, postmortem interval.

reductions in GCase activity results in the accumulation of the glycolipids glucosylceramide (GluCer) and glucosylsphingosine (GluSph). Heterozygous loss-of-function mutations in *GBA1* occur at a frequency of 4–7% in idiopathic PD patients.^{5–7} Approximately, 6–7% of early onset PD (<51 years) are carriers of either the N370S or L444P *GBA* mutations.⁸ These patients also develop clinical symptoms at an earlier age than nonmutation carriers.⁹ Moreover, PD patients who harbor a loss-of-function *GBA1* mutation usually develop more severe cognitive symptoms, are often diagnosed younger, and are associated with increased α -synuclein accumulation relative to non-*GBA1* mutation carrier (nonGBA1) PD patients.^{7,10–12} A recent report demonstrated that early stage nonGBA1 PD patients are associated with a reduction in GCase activity and dysfunctional lysosomes.¹¹ Despite the overwhelming evidence linking *GBA1* and diminished GCase activity with PD,^{7,12,13} it is presently unclear when this reduction occurs and how it is related to cellular aging and therefore its role the initiation and pathogenesis of the disease.

Elucidating some of the intracellular changes that occur with normal aging may give insight into the early changes that occur in PD. Our data suggest that aging lysosomes may contribute to the early pathology in PD and offers a broader perspective of how aging can lower the threshold and contribute to the onset of the disease. Here, we present data that show that GCase activity is reduced in non-GBA1 PD patients in the sixth, seven, and eight decade of life, which is associated with an increase in GluSph levels. Remarkably, healthy subject controls exhibit a gradual age-related reduction in GCase activity in the substantia nigra and putamen, which became evident during the seventh and eighth decade of life, respectively. These data suggest that GCase activity or more broadly diminished lysosomal function may be a critical age-related risk factor that increases the vulnerability of dopamine neurons and lower the threshold for developing PD.

Materials and Methods

Patients

Frozen postmortem brain tissue from male and female neurologically unaffected patients (healthy subject controls) and sporadic PD patients were provided by the Harvard Brain Tissue Resource Center (HBTRC; McLean Hospital, Belmont, MA). All PD cases met a pathological diagnosis of PD made by the brain bank, which was based on the extent of neuronal (pigment) loss in the substantia nigra and locus coeruleus (0–4), and Braak staging (0–6). Postmortem brains from healthy subject controls and PD patients were closely matched for age, sex, and postmortem interval (Table 1). All of the PD patient brain tissue

was sequenced for GBA1 mutations (the GBA1 pseudogene was taken into account) at Beckman Coulter Genomics (Danvers, MA) and any PD patient with a GBA1 mutation was removed from further analysis.

Glucocerebrosidase activity analysis

Brain tissue was resuspended in ice-cold MilliQ water and homogenized for 15 sec. A portion of the homogenate was used for protein determination (BCA Assay, Pierce, Pierce Biotechnology, Rockford/IL, USA). To determine GCase activity, brain homogenates were diluted in a 2 mg/mL bovine serum albumin, citric acid sodium phosphate buffer (pH 5). Ten microliter of sample was added to 75 μ L of 10 mmol/L 4-Mu- β -D-glucopyranoside (Sigma, Sigma-Aldrich, St. Louis, MO, USA) substrate. After incubation with the substrate for 60 min at 37°C, the reaction was terminated using a stop solution (0.3 mol/L glycine/0.2 mol/L sodium carbonate, pH 10.7). Plates were read (Ex 360/Em 460) using a Molecular Devices, Sunnyvale, CA SPECTRAMax plate reader. Enzymatic activity was assessed from a 4-Mu standard curve and normalized to protein content in each sample.

LC-MS/MS analysis GluSph

A 50- μ L aliquot of homogenate was used to prepare sample for the quantitation of GluSph. Eight hundred microliter of acetonitrile and methanol 1:1 solvent was used to extract GluSph from the tissue. The samples were sonicated, vortexed, and centrifuged before being transferred to injection plate for Liquid chromatography/tandem mass spectrometry (LC-MS/MS) analysis. For quantification of GluSph, 2 μ L of sample was injected onto a Supelco 2.1 mm i.d. \times 25 cm LC-Si HPLC (high-performance liquid chromatography) column (Sigma) connected to a Shimadzu LC Prominence UFLC solvent delivery system. The isocratic solvent system consisted of 0.08 mL/min mobile phase A (water) and 1.0 mL/min mobile phase B (CH₃CN/CH₃OH/CH₃COOH 97:2:1 with 5 mmol/L of ammonium formate). The Selected Reaction Monitoring transitions monitored for GluSph and the internal standard plant GluSph were m/z 462 to m/z 282 and m/z 460 to m/z 280, respectively.

Results

Glucocerebrosidase activity progressively declines in the substantia nigra with normal aging

Brain tissue from nonGBA1 mutation carrying sporadic PD patients was collected and GCase activity was mea-

sured in substantia nigra and putamen. Our data show a clear age-dependent decrease in GCase activity in the substantia nigra that spans the sixth to eighth decade of life ($r = -0.643$, $P < 0.001$) in healthy subject controls (Fig. 1A). A similar trend was also observed in the putamen across the sixth to eighth decade of life in healthy subject controls. This gradual decline in GCase activity in healthy subject controls became similar to nonGBA1 mutation carrying PD patients by the seventh decade in the substantia nigra ($F_{2,35} = 28.26$, $P < 0.0001$) and the eighth decade in the putamen ($F_{2,32} = 7.16$, $P < 0.05$). GluSph levels were increased in sporadic PD patients at the sixth decade of life ($F_{2,35} = 14.52$, $P < 0.001$) in the substantia nigra. We measured both GluCer and GluSph in sporadic PD patient tissue, however, due to an interfering peak, only GluSph was analyzed.

Glucocerebrosidase activity is decreased in the brains of sporadic PD patients coinciding with an accumulation of GluSph

GCase activity and levels of GluSph were also assayed in the frontal cortex, hippocampus, and cerebellum of non-GBA1 PD patients and age-matched healthy controls between their 70 and 80 years of age. GCase activity was significantly decreased in the hippocampus ($T_{1,8} = 2.405$, $P < 0.05$) and cerebellum ($T_{1,16} = 2.439$, $P < 0.05$) in nonGBA1 PD patients in comparison to age-matched controls. We found a significant increase in GluSph in the hippocampus ($T_{1,10} = 3.19$, $P < 0.05$) of nonGBA1 PD patients. There was a trend toward an increase for GluSph in the cerebellum of nonGBA1 PD patients in comparison to age-matched controls (Fig. 2B).

Discussion

Age-dependent reductions in GCase activity occur in normal aging and in sporadic PD patients

The involvement of GCase in the pathogenesis of PD is still not understood. Postmortem brain samples from nonGBA1 PD patients show a significant decrease in GCase activity and protein levels in the substantia nigra and cerebellum.¹⁴ We demonstrate for the first time that GCase activity gradually declines in the substantia nigra of healthy subject controls, eventually becoming comparable to PD patients by the seventh decade of life. Similarly, GCase activity also progressively declines in the putamen becoming comparable to PD patients by the eighth decade of life. Reductions in GCase activity may represent a progressive reduction in lysosomal function with normal aging, which may eventually become pathological




Figure 1. GCCase activity is gradually decreased in the substantia nigra and putamen during normal aging. Brain tissue homogenates from frozen postmortem brain samples were used for measurements of GCCase using a 4-methylumbelliferyl activity assay. (A) GCCase activity gradually decreased in the substantia nigra and the putamen over the sixth to eighth decade of life in healthy subjects. (B) GCCase activity remained consistently low in non-GBA mutation carrying PD patients across the sixth to eighth decade of life in comparison to healthy age-matched controls. (C) By the seventh and eighth decade of life GCCase activity levels in healthy subject controls looked similar to PD patients in the substantia nigra and putamen, respectively. GluSph levels were increased in sporadic PD patients at the sixth decade of life in the substantia nigra, but did not change in the putamen. * $P < 0.05$, two-way ANOVA with Bonferroni post hoc analysis, correlation analysis completed by Pearson test. $N = 23$ /disease cohort. Graphs are expressed as mean \pm SEM. GCCase, glucocerebrosidase; GluSph, glucosylsphingosine; PD, Parkinson's disease; SEM, standard error of the mean; ANOVA, analysis of variance.

to the cell. This is supported by recent evidence demonstrating that a reduction in GCCase activity accelerates the progression and symptoms of PD.^{12,15} This reduction in GCCase activity is accompanied by an accumulation of GluSph in the substantia nigra. This is the first report, to the best of our knowledge that has measured glycolipids

in the brain of PD patients. We observed the accumulation in GluSph in the substantia nigra may reflect diminished lysosomal clearance capacity.

Although PD is rare before age 40, the prevalence rises almost exponentially after 50 years of age.¹ It is possible that when the amount of functioning GCCase is reduced




Figure 2. GCase activity is decreased and GluSph is increased in sporadic PD patient brains. GCase is a lysosomal enzyme responsible for the hydrolysis of the lipid substrates GluCer into ceramide and glucose, and GluSph into sphingosine and glucose. Data show that GBA activity is diminished in the putamen, hippocampus, substantia nigra, and cerebellum of sporadic PD patients in comparison to age-matched controls (A). Diminished GBA activity corresponded to accumulation of GluSph in the hippocampus (B). * $P < 0.05$, unpaired t -test. $N = 6$ – 12 /group. Graphs are expressed as mean \pm SEM. GCase, glucocerebrosidase; GluSph, glucosylsphingosine; GluCer, glucosylceramide; PD, Parkinson's disease; SEM, standard error of the mean; ANOVA, analysis of variance.

below a critical level, it may directly influence lysosomal clearance capacity causing inefficient protein degradation, and may eventually become pathological promoting the accumulation of misfolded proteins, and dysfunctional mitochondria. GBA1 mutations are twice as common in early onset PD in comparison to late onset PD cases.⁸ PD patients with a heterozygous GBA1 mutation are associated with 30–50% reduction in GCase activity.¹² These patients usually develop the disease earlier and are associated with more advanced α -synuclein pathology.^{8,11} The motor impairments among GBA1 PD patients usually occur 6–7 years earlier in comparison to nonGBA1 PD patients.^{8,16} The data reported here indicate that with age, the levels of GCase activity in healthy subjects eventually reach a level of GCase reduction that is similar to GBA1 haploid insufficient PD patients. Given that the cell biological processes caused by GBA1 haploid-

insufficiency predispose individuals to PD by leading to early degeneration and α -synuclein pathology with onset of the disease in the sixth decade, it is therefore reasonable to assume that a 30–50% age-dependent reduction in GCase activity in the seventh and eighth decade of life (during normal aging) would significantly increase the risk for developing PD in a nonGBA1 carrier. Moreover, sporadic PD is likely caused by a combination of convergent mechanisms that include age-related risk factors that contribute to DA neuron vulnerability such as accumulation of dysfunctional mitochondria, deficits in protein degradation systems, and aggregated α -synuclein accumulation. These age-related biological deficits likely contribute to the exponential rise in PD in the seventh and eighth decade of life. Tracking GCase activity levels during aging and during the preclinical phase of the disease may provide a unique opportunity to identify changes

that occur prior to the pathophysiology that leads to the onset of PD symptoms.

Diminished GCase activity and GluSph accumulation occur in sporadic non-GBA mutation PD patients

We found widespread reduction in GCase activity in the cerebellum and hippocampus, in addition to the putamen and substantia nigra of sporadic PD patients that are non-GBA mutation carriers, which coincided with an increase in GluSph. These results show that the GluSph lipid substrate is accumulated in the brain of sporadic PD patients. It is possible that this accumulation of the GluSph disrupts intralysosomal homeostasis and promotes aggregation of α -synuclein, thus enhancing neuronal vulnerability. Recent observations have suggested a reciprocal relationship exists between GCase and α -synuclein.^{17,18} Moreover, a landmark finding supports this reciprocal relationship between GCase and α -synuclein by demonstrating that a partial loss of GCase activity can interfere with protein degradation in the lysosome, promote accumulation of α -synuclein, and enhance α -synuclein-mediated neurotoxicity.¹⁷ Therefore, accumulation of GluSph, and possibly GluCer, may contribute to the pathophysiology of PD by disrupting lysosomal function.

Acknowledgments

This work was supported by the Harvard Stem Cell Institute Translational Neuroscience Fund, the Harold and Ronna Cooper family, the Consolidated Anti-Aging Foundation, the Poul Hansen family, and the Canadian Institute of Health Research. We would like to thank the Harvard Brain Tissue Resource Center (Belmont, MA) for human tissue samples.

Conflict of Interest

None declared.

References

- Kasten M, Chade A, Tanner CM. Epidemiology of Parkinson's disease. *Handb Clin Neurol* 2007;83:129–151.
- Martinez-Vicente M, Sovak G, Cuervo AM. Protein degradation and aging. *Exp Gerontol* 2005;40:622–633.
- Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. *Nat Rev Mol Cell Biol* 2007;8:931–937.
- Chu CT, Zhu J, Dagda R. Beclin 1-independent pathway of damage-induced mitophagy and autophagic stress: implications for neurodegeneration and cell death. *Autophagy* 2007;3:663–666.
- Asselta R, Rimoldi V, Siri C, et al. Glucocerebrosidase mutations in primary parkinsonism. *Parkinsonism Relat Disord* 2014;20:1215–1220.
- Lees AJ, Hardy J, Revesz T. Parkinson's disease. *Lancet* 2009;373:2055–2066.
- Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. *Brain*. 2009;132(Pt 7):1783–1794.
- Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. *Lancet Neurol* 2012;11:986–998.
- Clark LN, Ross BM, Wang Y, et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. *Neurology* 2007;69:1270–1277.
- Bras J, Singleton A, Cookson MR, Hardy J. Emerging pathways in genetic Parkinson's disease: potential role of ceramide metabolism in Lewy body disease. *FEBS J* 2008;275:5767–5773.
- Murphy KE, Gysbers AM, Abbott SK, et al. Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease. *Brain* 2014. 137 (Pt 3):834–848.
- Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. *N Engl J Med* 2009;361:1651–1661.
- Gegg ME, Burke D, Heales SJ, et al. Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. *Ann Neurol* 2012;72:455–463.
- Galvin JE, Lee VM, Trojanowski JQ. Synucleinopathies: clinical and pathological implications. *Arch Neurol* 2001;58:186–190.
- Bras J, Paisan-Ruiz C, Guerreiro R, et al. Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. *Neurobiol Aging* 2009;30:1515–1517.
- Brockmann K, Surljies K, Pfloderer S, et al. GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study. *Mov Disord* 2014 [Epub ahead of print].
- Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. *Cell* 2011;146:37–52.
- Siebert M, Sidransky E, Westbroek W. Glucocerebrosidase is shaking up the synucleinopathies. *Brain*. 2014;137 (Pt 5):1304–1322.